Company Overview of Revalesio Corporation
Revalesio Corporation, a biotechnology company, develops therapeutics for the treatment of inflammatory diseases. It offers respiratory, cardiovascular, neuroscience, orthopedic, wound care, and oncology products. The company was formerly known as Microdiffusion, Inc. and changed its name to Revalesio Corporation in August 2007. Revalesio Corporation was founded in 2000 and is based in Tacoma, Washington.
1200 East D Street
Tacoma, WA 98421
Founded in 2000
Key Executives for Revalesio Corporation
Chairman and Chief Executive Officer
Director of Clinical Sciences
Compensation as of Fiscal Year 2014.
Revalesio Corporation Key Developments
Revalesio Corporation Appoints Bert van den Bergh as President
Oct 20 14
Revalesio Corporation announced that the appointment of Bert van den Bergh as President. Mr. van den Bergh brings extensive industry experience to Revalesio as the company accelerates the development and commercialization of its therapeutic, RNS60. He previously spent 30 years with Eli Lilly & Company where he served as President of Neuroscience Products, President of European Operations and General Manager for the United Kingdom and Germany. In addition to his role at Revalesio, van den Bergh serves on a variety of nonprofit boards and advisory committees, including the Pulmonary Vascular Research Institute, Mental Health America and Peers for Progress.
Revalesio Corporation Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich
Nov 11 13
Revalesio Corporation announced a new collaboration with neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis (RRMS or MS). The study will compare measurements of disease activity and progression in patients with RRMS during 6-months treatment with RNS60. The open label study will enroll 15 patients and evaluate the use of RNS60 by intravenous administration compared to patient's pre-treatment disease activity. The main outcome of the study will be the reduction of inflammatory activity in the brain as measured by Gd contrast-enhacing MRI lesions. Additional measures include progression of disability and biomarkers for RNS60 and general inflammation. The study will be conducted at the University Hospital Zurich in Switzerland and at Innsbruck Medical University in Innsbruck, Austria. RNS60 has been tested in numerous pre-clinical models of MS and has shown the ability to halt disease progression by limiting glial infiltration (inflammation in the brain), protecting myelin and enriching the regulatory T-cell (TREG) populations in animals treated with RNS60.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 21, 2014
Most Searched Private Companies
Sponsored Financial Commentaries